Michael Didocha Joins Telix as Chief Financial Officer, Americas
Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas region.
Samantha McSherry Joins Telix as Director of Commercial Operations ANZ
Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New Zealand.
Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
AUDIO LINK NOT ATTACHED – Telix Half-Year Results 2021 and Company Update Conference Call
Telix announces Half-Year Results 2021 and provides shareholder update
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with GenesisCare.
Telix H1 2021 Results and Company Update Conference Call
Telix to hold investor conference call to present H1 2021 financial results and Company update.
Activities Report and Appendix 4C for June 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June 2021.
Telix Update on FDA New Drug Application Review for Illuccix®
Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product Illuccix®.
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA Association.
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68 generator.